Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): Study protocol for a randomized controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Kingsbury, Sarah R ^a   Tharmanathan, Puvan ^b   Arden, Nigel K ^c   Batley, Michael ^d   Birrell, Fraser ^e   Cocks, Kim ^b   Doherty, Michael ^f   Edwards, Chris J ^g   Garrood, Toby ^h   Grainger, Andrew J ^a   Green, Michael ⁱ   Hewitt, Catherine ^b   Hughes, Rod ^j   Moots, Robert ^k   O'Neill, Terence W ^l   Roddy, Edward ^m   Scott, David L ⁿ   Watt, Fiona E ^o,p   Torgerson, David J ^b   Conaghan, Philip G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁱ YORK HOSPITAL   (United Kingdom)

^j ST PETER S HOSPITAL   (United Kingdom)

^k UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m KEELE UNIVERSITY   (United Kingdom)

ⁿ KING S COLLEGE HOSPITAL   (United Kingdom)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Double blind; Knee osteoarthritis; Methotrexate; Placebo controlled; Randomized

Indexed keywords

METHOTREXATE; PLACEBO; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; KIDNEY FAILURE; KNEE FUNCTION; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SECONDARY CARE CENTER; SELF REPORT; SYNOVITIS; TREATMENT DURATION; UNITED KINGDOM; ARTHRALGIA; CLINICAL TRIAL; INTENTION TO TREAT ANALYSIS; METHODOLOGY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANALGESICS; ANTI-INFLAMMATORY AGENTS; ARTHRALGIA; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; HUMANS; INTENTION TO TREAT ANALYSIS; LINEAR MODELS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; METHOTREXATE; MULTIVARIATE ANALYSIS; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; RESEARCH DESIGN; SYNOVITIS; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84928804424     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0602-8     Document Type: Article

References (65)

1. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-223. doi:10.1016/S0140-6736(12)61689-4.
2. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96. doi:10.1016/S0140-6736(12)61729-2.
3. Murphy L, Schwartz TA, Helmick CG, Renner JB, Tudor G, Koch G, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008;59(9):1207-13. doi:10.1002/art.24021.
4. Bitton R. The economic burden of osteoarthritis. Am J Manag Care. 2009;15 Suppl 8:S230-5.
5. Care A. OA Nations Survey. 2003.
6. Hiligsmann M, Cooper C, Arden N, Boers M, Branco JC, Luisa Brandi M, et al. Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2013;43(3):303-13. doi:10.1016/j.semarthrit.2013.07.003.
7. National Institute for Health and Care Excellence. Osteoarthritis: care and management in adults. NICE Clinical Guideline 177. February 2014. http://www.nice.org.uk/guidance/CG177 Accessed 4 Aug 2014.
8. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-88. doi:10.1016/j.joca.2014.01.003.
9. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465-74.
10. Conaghan PG, Porcheret M, Kingsbury SR, Gammon A, Soni A, Hurley M et al. Impact and therapy of osteoarthritis: the Arthritis Care OA Nation 2012 survey. Clin Rheumatol. 2014. doi:10.1007/s10067-014-2692-1.
11. National population projections, 2008-based. Office for National Statistics. 2009. http://www.ons.gov.uk/ons/rel/npp/national-population-projections/2008-based-projections/index.html Accessed 19 Feb 2015.
12. Proceedings of the bone and joint decade 2000-2010 for prevention and treatment of musculo-skeletal disorders; 1998 April 17-18; Lund, Sweden. Acta Orthop Scand Suppl. 1998;281:1-86.
13. D'Agostino MA, Conaghan P, Le Bars M, Baron G, Grassi W, Martin-Mola E, et al. EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis. Ann Rheum Dis. 2005;64(12):1703-9. doi:10.1136/ard.2005.037994.
14. Ostergaard M, Stoltenberg M, Lovgreen-Nielsen P, Volck B, Jensen CH, Lorenzen I. Magnetic resonance imaging-determined synovial membrane and joint effusion volumes in rheumatoid arthritis and osteoarthritis: comparison with the macroscopic and microscopic appearance of the synovium. Arthritis Rheum. 1997;40(10):1856-67. doi:10.1002/1529-0131(199710)40:10<1856::AID-ART20>3.0.CO;2-3.
15. Peterfy CG, Majumdar S, Lang P, van Dijke CF, Sack K, Genant HK. MR imaging of the arthritic knee: improved discrimination of cartilage, synovium, and effusion with pulsed saturation transfer and fat-suppressed T1-weighted sequences. Radiology. 1994;191(2):413-9.
16. Keen HI, Wakefield RJ, Grainger AJ, Hensor EM, Emery P, Conaghan PG. An ultrasonographic study of osteoarthritis of the hand: synovitis and its relationship to structural pathology and symptoms. Arthritis Rheum. 2008;59(12):1756-63. doi:10.1002/art.24312.
17. Hill CL, Gale DG, Chaisson CE, Skinner K, Kazis L, Gale ME, et al. Knee effusions, popliteal cysts, and synovial thickening: association with knee pain in osteoarthritis. J Rheumatol. 2001;28(6):1330-7.
18. Hill CL, Hunter DJ, Niu J, Clancy M, Guermazi A, Genant H, et al. Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis. Ann Rheum Dis. 2007;66(12):1599-603. doi:10.1136/ard.2006.067470.
19. Goldring MB. Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther. 2001;1(5):817-29. doi:10.1517/14712598.1.5.817.
20. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol. 1997;24(2):365-71.
21. Myers SL, Brandt KD, Ehlich JW, Braunstein EM, Shelbourne KD, Heck DA, et al. Synovial inflammation in patients with early osteoarthritis of the knee. J Rheumatol. 1990;17(12):1662-9.
22. Brandt KD, Mazzuca SA, Buckwalter KA. Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees. Rheumatology (Oxford). 2006;45(11):1389-94. doi:10.1093/rheumatology/kel100.
23. Gineyts E, Mo JA, Ko A, Henriksen DB, Curtis SP, Gertz BJ, et al. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis. 2004;63(7):857-61. doi:10.1136/ard.2003.007302.
24. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133(8):635-46. doi:200010170-00016.
25. Ravaud P, Moulinier L, Giraudeau B, Ayral X, Guerin C, Noel E, et al. Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial. Arthritis Rheum. 1999;42(3):475-82. doi:10.1002/1529-0131(199904)42:3<475::AID-ANR12>3.0.CO;2-S.
26. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;2, CD005328. doi:10.1002/14651858.CD005328.pub2.
27. Jones A, Doherty M. Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response. Ann Rheum Dis. 1996;55(11):829-32.
28. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):455-74.
29. Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010;49(2):295-307. doi:10.1093/rheumatology/kep366.
30. Mease P. Methotrexate in psoriatic arthritis. Bull Hosp Jt Dis (2013). 2013;71 Suppl 1:S41-5.
31. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25(1):33-9. doi:S1471490603003582.
32. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57(2):163-72. doi:10.1124/pr.57.2.3.
33. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum. 1994;37(10):1492-8.
34. van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44(7):1515-24. doi:10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7.
35. Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross WL. Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol Int. 1996;15(5):195-200.
36. Salaffi F, Carotti M, Sartini A, Cervini C. A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis. Clin Exp Rheumatol. 1995;13(1):23-8.
37. de Holanda HT, Pollak DF, Pucinelli ML. Low-dose methotrexate compared to placebo in the treatment of knee osteoarthritis. Rev Bras Reumatol. 2007;47(5):334-40.
38. Pavelka K, Olejarova M, Pavelkova A. Methotrexate in the treatment of erosive OA of the hands. Ann Rheum Dis. 2006;65(Suppl II):402.
39. Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007;56(2):688-92. doi:10.1002/art.22389.
40. Wenham CY, Grainger AJ, Hensor EM, Caperon AR, Ash ZR, Conaghan PG. Methotrexate for pain relief in knee osteoarthritis: an open-label study. Rheumatology (Oxford). 2013;52(5):888-92. doi:10.1093/rheumatology/kes386.
41. Neidel J, Schroers B, Sintermann F. The effects of high-dose methotrexate on the development of cartilage lesions in a lapine model of osteoarthrosis. Arch Orthop Trauma Surg. 1998;117(4-5):265-9.
42. Mannoni A, Altman RD, Muniz OE, Serni U, Dean DD. The effects of methotrexate on normal and osteoarthritic lapine articular cartilage. J Rheumatol. 1993;20(5):849-55.
43. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68(7):1086-93. doi:10.1136/ard.2008.094474.
44. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094-9. doi:10.1136/ard.2008.092668.
45. Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;5, CD000951. doi:10.1002/14651858.CD000951.pub2.
46. Chang L. A psychometric evaluation of 4-point and 6-point Likert-type scales in relation to reliability and validity applied psychological measurements. Appl Psychol Meas. 1994;18(3):205-15.
47. Dworkin RH, Peirce-Sandner S, Turk DC, McDermott MP, Gibofsky A, Simon LS, et al. Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database. Osteoarthritis Cartilage. 2014;19(5):483-92.
48. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1-2):9-19. doi:10.1016/j.pain.2004.09.012.
49. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106(3):337-45.
50. Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, et al. Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain. 2008;137(2):276-85. doi:10.1016/j.pain.2007.09.002.
51. Hunter DJ, Guermazi A, Lo GH, Grainger AJ, Conaghan PG, Boudreau RM, et al. Evolution of semi-quantitative whole joint assessment of knee OA: MOAKS (MRI Osteoarthritis Knee Score). Osteoarthritis Cartilage. 2011;19(8):990-1002. Erratum in. Osteoarthritis Cartilage. 2011;19(9):1168.
52. Bowes MA, Vincent GR, Wolstenholme CB, Conaghan PG. A novel method for bone area measurement provides new insights into osteoarthritis and its progression. Ann Rheum Dis. 2015;74(3):519-25. doi:10.1136/annrheumdis-2013-204052.
53. Farrar JT, Young Jr JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149-58.
54. Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8(4):283-91. doi:10.1016/j.ejpain.2003.09.004.
55. Fukuda TY. Alves da Cunha R, Fukuda VO, Rienzo FA, Cazarini Jr C, Carvalho Nde A, et al. Pulsed shortwave treatment in women with knee osteoarthritis: a multicenter, randomized, placebo-controlled clinical trial. Phys Ther. 2011;91(7):1009-17. doi:10.2522/ptj.20100306.
56. Bennell KL, Bowles KA, Payne C, Cicuttini F, Williamson E, Forbes A, et al. Lateral wedge insoles for medial knee osteoarthritis: 12 month randomised controlled trial. BMJ. 2011;342:d2912. doi:10.1136/bmj.d2912.
57. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med. 1990;9(1-2):65-71. discussion 71-2.
58. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
59. Murphy SL, Lyden AK, Smith DM, Dong Q, Koliba JF. Effects of a tailored activity pacing intervention on pain and fatigue for adults with osteoarthritis. Am J Occup Ther. 2010;64(6):869-76.
60. Little CB, Smith MM, Cake MA, Read RA, Murphy MJ, Barry FP. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in sheep and goats. Osteoarthritis Cartilage. 2010;18 Suppl 3:S80-92. doi:10.1016/j.joca.2010.04.016.
61. Murphy LB, Helmick CG, Schwartz TA, Renner JB, Tudor G, Koch GG, et al. One in four people may develop symptomatic hip osteoarthritis in his or her lifetime. Osteoarthritis Cartilage. 2010;18(11):1372-9. doi:10.1016/j.joca.2010.08.005.
62. Coleman CM, Curtin C, Barry FP, O'Flatharta C, Murphy JM. Mesenchymal stem cells and osteoarthritis: remedy or accomplice? Hum Gene Ther. 2010;21(10):1239-50. doi:10.1089/hum.2010.138.
63. Murphy CL. HIF-2alpha-a mediator of osteoarthritis? Cell Res. 2010;20(9):977-9. doi:10.1038/cr.2010.99.
64. Conaghan PG, Porcheret M, Gammon A, Soni A, Hurley M, Rayman M, et al. The personal impact of osteoarthritis on individuals and how they use therapies: the arthritis care OA Nation 2012 Survey. Ann Rheum Dis. 2012;71 Suppl 3:584.
65. Abou-Raya A, Abou-Raya S, Khadrawe T. Methotrexate in the treatment of symptomatic knee osteoarthritis: randomised placebo-controlled trial. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204856.